Condition (MeSH)
Encephalomyelitis, Autoimmune, Experimental
ClinicalTrials.gov lists 1 trial for Encephalomyelitis, Autoimmune, Experimental or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Encephalomyelitis, Autoimmune, Experimental itself; the rest are tagged with a narrower condition beneath it.
When did Encephalomyelitis, Autoimmune, Experimental trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2021 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Encephalomyelitis, Autoimmune, Experimental trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 1 |
How many Encephalomyelitis, Autoimmune, Experimental trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Encephalomyelitis, Autoimmune, Experimental? (209)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway. | International immunopharmacology | 2023 | Yes |
| MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis. | Neuropathology and applied neurobiology | 2022 | Yes |
| PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis. | Frontiers in immunology | 2022 | Yes |
| Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis. | International journal of molecular sciences | 2022 | Yes |
| Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone. | Behavioural brain research | 2021 | Yes |
Showing 5 of 209 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.